Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Estimated read time 1 min read
Posted in Medicine

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

admin

Biogen Inc.

Biogen Inc.

TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the…

[ad_2]

Source link

You May Also Like

More From Author

Rebecca Kennedy’s 3 Day Split Strength Program on Peloton (Intermediate)

Rebecca Kennedy’s 3 Day Split Strength Program on Peloton (Intermediate)

Harris under pressure on border security in White House bid

Harris under pressure on border security in White House bid

Leave a Reply

Your email address will not be published. Required fields are marked *